We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of Bioventus Inc. (NASDAQ: BVS) (“Bioventus” or the “Company”) commencing with the Company’s initial public offering (“IPO”).

Bioventus conducted an Initial Public Offering (“IPO”) on February 11, 2021, of 8 million shares of its common stock at $13 per share, raising $104 million, without disclosing that significant liquidity issues plagued the Company, that it had insufficient internal and disclosure controls to properly account for drug rebates, chargebacks and discounts to pharmacy and health benefit managers, and –therefore– it could not ensure the accuracy of its operating results and financial condition. Almost two years later, in November 2022, the Company reported approximately $200 million in non-cash impairment charges, that its misaccounted rebate claims would negatively impact the Company’s previously announced financial results, and that the ongoing material weakness in its internal controls would result in the Company’s inability to meet its financial obligations and its inability to timely file its Quarterly Report for the third quarter of 2022. The Company’s stock has dropped more than 86% since its February 11, 2021 IPO.

Weiss Law has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties.  We have recovered over a billion dollars for defrauded clients.  For more information about the firm, please go to: http://www.weisslaw.co